公开(公告)号：US08007776B2

公开(公告)日：2011-08-30

申请号：US10529923

申请日：2003-10-08

申请人： Alicia Santos Savio ,  Ricardo Silva Rodriguez ,  Yanelis Morera Diaz ,  Armando Alexei Rodriquez Alfonso ,  Jose Rafael Martinez Castillo ,  Haydee Geronimo Perez ,  Alejandro Moro Soria ,  Silvio Ernesto Perea Rodriguez

发明人： Alicia Santos Savio ,  Ricardo Silva Rodriguez ,  Yanelis Morera Diaz ,  Armando Alexei Rodriquez Alfonso ,  Jose Rafael Martinez Castillo ,  Haydee Geronimo Perez ,  Alejandro Moro Soria ,  Silvio Ernesto Perea Rodriguez

IPC分类号： A61K38/20

CPC分类号： A61K39/0005

摘要： Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host.IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide.Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

摘要翻译： 含有IL-15的疫苗组合物用于主动免疫治疗与该细胞因子的过表达有关的疾病。 在本发明中追求的技术目的是通过开发在免疫宿主中引发IL-15中和抗体的治疗性疫苗来抑制IL-15活性。 IL-15可以单独存在于该疫苗组合物中，也可以与诸如氢氧化铝等疫苗佐剂的载体例如P64k蛋白偶联。 此外，本发明涉及该疫苗用于治疗类风湿性关节炎和其它IL-15过表达相关疾病和白血病，其中该细胞因子作为生长因子。

公开(公告)号：US07736638B2

公开(公告)日：2010-06-15

申请号：US11662844

申请日：2005-09-16

申请人： Alicia Santos Savio ,  Ania Cabrales Rico ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Celia Aurora Arrieta Aguero ,  Silvio Ernesto Perea Rodriguez

发明人： Alicia Santos Savio ,  Ania Cabrales Rico ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Celia Aurora Arrieta Aguero ,  Silvio Ernesto Perea Rodriguez

IPC分类号： A61K38/20 ,  C12N15/06 ,  C07K14/54 ,  C12N5/02 ,  C12P21/02

CPC分类号： C07K14/5443 ,  A61K38/00 ,  A61K39/00 ,  C07K16/244

摘要： Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15Rα) and TNFα-mediated apoptosis.Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15Rα expression is associated to the disease progression.

摘要翻译： 本发明涉及分子药理学分支，特别是涉及能够抑制IL-15生物活性，类似物或模拟这些肽的白细胞介素-15序列（IL-15）的肽。 在本发明中，显示肽结合IL15受体a亚基（IL15Rα）和TNFα介导的细胞凋亡后，抑制IL-15诱导的T细胞增殖。 此外，本发明涉及该肽用于治疗其中异常IL-15或IL-15Rα表达与疾病进展相关的几种病症的用途。

公开(公告)号：US20090136511A1

公开(公告)日：2009-05-28

申请号：US11662844

申请日：2005-09-16

申请人： Alicia Santos Savio ,  Ania Cabrales Rico ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Celia Aurora Arrieta Aguero ,  Silvio Ernesto Perea Rodriguez

发明人： Alicia Santos Savio ,  Ania Cabrales Rico ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Celia Aurora Arrieta Aguero ,  Silvio Ernesto Perea Rodriguez

IPC分类号： A61K38/08 ,  C07K7/06 ,  A61K39/00 ,  A61K39/395 ,  A61P19/02 ,  A61P17/06 ,  C07K16/00 ,  C07H21/00

CPC分类号： C07K14/5443 ,  A61K38/00 ,  A61K39/00 ,  C07K16/244

摘要： Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor α subunit (IL15Rα) and TNFα-mediated apoptosis.Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15Rα expression is associated to the disease progression.

摘要翻译： 本发明涉及分子药理学分支，特别是涉及能够抑制IL-15生物活性，类似物或模拟这些肽的白细胞介素-15序列（IL-15）的肽。 在本发明中，显示该肽在结合IL15受体α亚基（IL15Rα）和TNFα介导的细胞凋亡时抑制IL-15诱导的T细胞增殖。 此外，本发明涉及该肽用于治疗其中异常IL-15或IL-15Rα表达与疾病进展相关的若干病理学的用途。

公开(公告)号：US08431524B2

公开(公告)日：2013-04-30

申请号：US13120855

申请日：2009-09-30

申请人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enríque Guillen Nieto

发明人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enríque Guillen Nieto

IPC分类号： A61K38/04 ,  C12Q1/68

CPC分类号： C07K14/5443 ,  A61K38/00

摘要： The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor α subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

摘要翻译： 本发明涉及分子免疫学领域，特别涉及衍生自白介素-15（IL-15）序列的肽，其中所述肽被优化以抑制该分子的生物学活性。 在本发明中，显示该肽抑制IL-15诱导的T细胞增殖，肿瘤坏死因子α（TNFalpha）诱导和IL-8受体α亚基（IL）的IL-8和IL-6的表达 -15Rα），所有这些作用由肽与IL-15Rα的结合介导。 本发明还涉及使用肽来治疗其中IL-15或IL-15Rα异常表达与疾病进程如类风湿性关节炎（RA）和前列腺癌相关的病理学。

公开(公告)号：US20110251140A1

公开(公告)日：2011-10-13

申请号：US13120855

申请日：2009-09-30

申请人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enrique Guillen Nieto

发明人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enrique Guillen Nieto

IPC分类号： A61K38/08 ,  C07H21/00 ,  A61P19/02 ,  A61P35/00 ,  A61P17/06 ,  A61P29/00 ,  C07K7/06 ,  C12N15/63

CPC分类号： C07K14/5443 ,  A61K38/00

摘要： The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor a subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

摘要翻译： 本发明涉及分子免疫学领域，特别涉及衍生自白介素-15（IL-15）序列的肽，其中所述肽被优化以抑制该分子的生物学活性。 在本发明中，表明该肽抑制IL-15诱导的T细胞增殖，肿瘤坏死因子α（TNFα）诱导和IL-8受体a亚基（IL）的IL-8和IL-6的表达 -15Rα），所有这些作用由肽与IL-15Rα的结合介导。 本发明还涉及使用肽治疗其中IL-15或IL-15Rα的异常表达与疾病进程相关的病症，例如类风湿性关节炎（RA）和前列腺癌。

公开(公告)号：US20050107294A1

公开(公告)日：2005-05-19

申请号：US10499457

申请日：2002-12-04

申请人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K9/08 ,  A61K9/14 ,  A61K9/19 ,  A61K38/00 ,  A61K38/18 ,  A61P9/10 ,  A61P17/02 ,  C07K14/485

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，以及（ii）皮肤缺血性损伤的瘢痕化，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以发rise和/或愈合的溃疡或其它病变。

公开(公告)号：US07799760B2

公开(公告)日：2010-09-21

申请号：US12197001

申请日：2008-08-22

申请人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K38/18 ,  C07K14/485

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，（ii）皮肤缺血性损伤的瘢痕形成，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以瘢痕和/或愈合的溃疡或其他损伤。

公开(公告)号：US20080312139A1

公开(公告)日：2008-12-18

申请号：US12197001

申请日：2008-08-22

申请人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K38/39 ,  C07K14/485 ,  A61P9/10 ,  A61K38/18

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-Injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，和（ii）皮肤缺血性损伤的瘢痕化，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以发rise和/或愈合的溃疡或其它病变。